News | May 25, 2026
Oral GLP-1 race heats up as Lilly’s Foundayo shines in seniors
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
The standout story remains Wegovy, particularly its new oral formulation
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
Lifts full-year outlook as obesity drug boom accelerates
The Danish biotech company confirmed the global study will begin in the second half of 2026
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
